Pierre Fabre Pushes for Urgent FDA Meeting to Salvage U.S. Approval for Rejected Cell Therapy Ebvallo

This analysis is based on reporting originally published by BioPharma Dive. For daily updates on the pharmaceutical industry, subscribe to the BioPharma Dive newsletter.

French pharmaceutical group Pierre Fabre is mounting a last-ditch effort to revive U.S. prospects for Ebvallo, a cell therapy for a lethal transplant complication, after the Food and Drug Administration delivered its second rejection earlier this year. The therapy, designed for patients with post-transplant lymphoproliferative disease (PTLD) linked to Epstein-Barr virus, won European approval in late 2022 but has repeatedly stumbled at the FDA's door.

PTLD is a fast-moving and often fatal condition where B cells proliferate uncontrollably following an organ or stem cell transplant, frequently manifesting as lymphoma. While existing treatments like Rituxan can help, a significant portion of patients do not respond, leaving them with limited options and a grim prognosis measured in weeks or months.

In response to the latest setback, Pierre Fabre—which holds global commercial rights to Ebvallo—has formally requested a high-priority "Type A" meeting with the FDA. These meetings, mandated to occur within 30 days of request, are reserved for critical discussions on clinical holds, trial design disputes, or stalled applications. The move signals a strategic push to clarify the agency's concerns and potentially fast-track a revised pathway to approval.

"We are approaching this with urgency, backed by strong advocacy from patients and physicians," stated Adriana Herrera, CEO of Pierre Fabre's U.S. subsidiary. "For those who fail standard treatment, time is brutally short. Every week of delay has real consequences."

The rejection has left analysts and investors perplexed, given Ebvallo's previous regulatory endorsements. Developer Atara Biotherapeutics (which licensed the therapy to Pierre Fabre) noted that the FDA had previously aligned on the trial design through multiple meetings over five years, and had granted the therapy both Breakthrough Therapy and Orphan Drug designations.

Some industry observers see the case as indicative of broader regulatory unpredictability. "We're witnessing what appears to be a top-down recalibration of standards at the FDA," wrote Cantor Fitzgerald analyst Eric Schmidt in a January note, after discussions with Atara's leadership. "For companies developing therapies for unmet needs, these seemingly abrupt shifts create significant uncertainty."

Voices from the Field:

Dr. Lena Rodriguez, Transplant Oncologist at Midwest Medical Center: "This therapy addresses a dire gap in our arsenal. The clinical data supporting it is robust, and the European approval wasn't granted lightly. The FDA's hesitation is puzzling and, frankly, disheartening for families waiting for a lifeline."

Michael Pearce, Healthcare Portfolio Manager at Horizon Capital: "This isn't just about one drug. It's about signal risk. The FDA's evolving stance under current leadership is injecting volatility into the entire rare disease investment thesis. If designations like 'Breakthrough Therapy' don't translate into a coherent review pathway, what's their value?"

Sarah Chen, Patient Advocate whose son is a PTLD survivor: "It's infuriating. We have a treatment that works and is available elsewhere, but bureaucracy is keeping it from dying patients here. The FDA talks about patient-centricity, but where is the urgency? Every day of discussion is a day someone loses."

Prof. David Klein, Bioethics Researcher at Sterling University: "The tension here is between regulatory rigor and compassionate flexibility. While the FDA must ensure absolute safety and efficacy, its communication and consistency are crucial. Cases like this can erode trust in the regulatory process from all stakeholders."